Lv1
60 积分 2024-09-06 加入
[Cancer incidence and mortality across diverse geographical regions in China, 2024]
8天前
已完结
Tests for Circulating Immune Complexes
22天前
已完结
Circulating Immune Complexes: Their Immunochemistry, Detection, and Importance
22天前
已完结
Interleukin 2 receptor antagonists for kidney transplant recipients
1个月前
已完结
Fulzerasib plus cetuximab in first-line KRAS-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial
1个月前
已完结
Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial
3个月前
已完结
Clinical Impact of Hepatic Impairment on the Pharmacokinetics of Sotorasib and Its Major Metabolites: Implications for Dose Adjustment
4个月前
已完结
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
5个月前
已完结
Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas
5个月前
已完结
Sotorasib nel carcinoma polmonare non a piccole cellule con mutazione KRAS G12C: dall’evidenza alla pratica clinica
6个月前
已完结
皖公网安备34019202002308
